Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Drug resistance

Triple-combination therapy prevents drug resistance in colorectal cancer cells

After finding that triple-combination therapy may help to prevent resistance acquisition in colorectal cancer cells, the researchers said that future studies should look into questions of timing, dosage and tolerability.

Colon cancer micrograph

Source: Steve Gschmeissner / Science Photo Library

The researchers said the findings indicated that triple-combination therapy for colon cancer (micrograph pictured) may help to prevent resistance acquisition

Treating colorectal cancer with a trio of targeted drugs reduces the acquisition of drug resistance, in vitro research published in Oncogene shows (25 March 2019)[1].

Researchers treated a panel of 47 human colorectal cancer cell lines with combinations of MEK- PI3K- and ERK-inhibitors. These signalling pathways are frequently activated in colorectal tumours.

They found that treating cells with a MEK-PI3K-inhibitor combination led to a synergistic effect in cell growth inhibition. Cells that acquired resistance could be successfully treated with an ERK-PI3K regimen, but subsequently developed resistance to this treatment regimen too.

However, adding a low concentration of navitoclax, a BCL2-family inhibitor, to the MEK-PI3K regimen in previously untreated cells resulted in improved synergistic interaction between the therapies and blocked the acquisition of resistance.

The researchers said the findings indicated that triple-combination therapy may help to prevent resistance acquisition, rather than overcoming pre-existing resistance. Future studies should look into the questions of timing, dosage and tolerability, they added.

“It is possible that the addition of a third agent may be tolerated clinically in such a dosing regimen and provide the opportunity to overcome, or ameliorate, the major clinical problem of resistance to targeted therapies,” they concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206504

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Prescribing Adult Intravenous Nutrition

    Prescribing Adult Intravenous Nutrition

    A practical guide to the principles and practice of adult intravenous nutrition. With numerous illustrations and case studies.

    £40.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.